Innovative Scientific Team Increases Cardiac Biomarker Product line For Cardiovascular Disease Management

Share Article

Cardiac biomarker production is at an all time high for a leading producer of finished proteins, Lee Biosolutions. Increased business is seen for next year for this innovative company.

Lee Biosolutions Scientific Team

70 individuals die each hour in the U.S from heart disease.

Lee Biosolutions Inc, a U.S. manufacturer, producer and supplier of finished high purity proteins and antigens announces an increased production for high valued cardiac biomarkers do to securing new business for 2013. The St. Louis-based healthcare- biotechnology firm has developed a unique proprietary process to effectively and efficiently purify an extensive portfolio of cardiac biomarkers for Cardiovascular Disease (CVD) testing. As a result, Lee is the preferred supplier for worldwide Invitro- diagnostic companies to provide consistent high quality stable critical components used in diagnostic panel of assays that are designed to help improve risk assessment, early diagnosis, prognosis and monitoring of CVD.

According to the Centers of Disease Control and Prevention there will be a close to a million Americans that will have a heart attack this year do to risk factors such as diabetes, being overweight, continued poor diet, physical inactivity or excessive alcohol use. Did you know that 70 people die each hour in the United States from heart disease and stroke and 17 million people will die worldwide. The cost in the U.S. alone is a staggering 106 billion dollars for our economy just for healthcare, medications and lost productivity in the work place.

Burton Lee , President of Lee Biosolutions says “We are a recognized leader in the purification of cardiac biomarkers for the clinical diagnostic market because of our strong innovative scientific team. Due the advancements in the understanding of the pathogenesis of heart disease and studies showing a need to use a diverse set of biomarkers when managing and assessing a patient, our clients are requiring a wider portfolio of cardiac markers. For instance, there are three major areas where our cardiac proteins are now being used in are dedicated chemistry, point of care and immunoassay systems: Dyslipidemia, Atherosclerosis and Acute Coronary Syndrome. Dyslipidemia is characterized by abnormal amount of lipids and we provide products such as cholesterol , high density lipoprotein, low density lipoproteins, APO A1 and triglycerides that are formulated in these tests. Atherosclerosis is the hardening of the arteries where there is a build-up of plaque in the inner walls that results in reduced flow of oxygen-rich blood and tests now are using our fibrinogen, c-reactive protein and myeloperoxidase products. Acute Coronary Syndrome (ACS) which we all know as that sudden heart attack, basically reflects the damage done to the coronaries by atherosclerosis from reduced blood flow to the heart muscle, starving it of oxygen and leading to the heart muscles failure or death.    Our clients have qualified our Cardiac Troponin I I and Troponin T, CKMB, BNP, NT-ProBNP and Myoglobin . As demand grows so will our product line due to our scientific knowledge and experience. “

About Lee BioSolutions, Inc.
Lee BioSolutions is an international producer and supplier of high purity finished proteins. Headquartered in St. Louis and founded in 2002, the healthcare biotechnology firm serves academic and scientific researchers as well as IVD manufacturers worldwide.    Lee BioSolutions produces and processes raw biomaterials used in drug discovery and development, laboratory te,clinical diagnosis and product testing . LeeBio has a large Facebook fan base at . The company is ISO 9001:2008 certified, FDA registered and meets USDA guidelines. To learn more about Lee BioSolutions visit or call 314-968-1091.

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Burton Lee
Email >
Visit website